PF4 and systemic sclerosis: Here, we have tried to understand what is the distribution of anti-CXCL4 and anti-CXCL4-L1 antibody reactivity in SSc (either eaSSc or lsSSc) and VEDOSS patients (either SSc-progressors and SSc-non-progressors), to indentify new biomakers of disease/disease progression and new players in SSc pathogenesis.